Novo Nordisk Rebrands Rybelsus as Ozempic to Increase Patient Awareness

On February 4, 2026, the US Food and Drug Administration approved Ozempic as the proprietary name for Novo Nordisk’s oral semaglutide formulation 1.5 mg, 4 mg, and 9 mg for adult patients with type 2 diabetes. The pill’s active ingredient is the same as the treatment previously known as Rybelsus, meaning the change is effectively a rebrand of an existing drug. Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the decision and its expected impact on patient awareness of the drug’s availability and efficacy. Check out the full episode on oral GLP-1s at https://www.hcplive.com/view/diabetes.... Key Timestamps 00:00:01 Oral Wegovy announcement 00:00:46 Why oral Ozempic isn't new 00:02:50 Why rebrand Rybelsus? 00:03:58 Patient awareness of oral semaglutide 00:04:29 Ozempic dosing limitations #ozempic #diabetes #rybelsus #novonordisk